Icecure Medical (ICCM) has released an update.
IceCure Medical has received a favorable recommendation from the FDA Advisory Panel for its ProSense® cryoablation system, designed to treat early-stage low risk breast cancer by freezing tumors as an alternative to surgery. This milestone brings the company closer to securing FDA marketing authorization, expected in early 2025, which could offer a new treatment option for patients. The decision underscores the potential of ProSense® to transform breast cancer care and boost IceCure’s market presence.
For further insights into ICCM stock, check out TipRanks’ Stock Analysis page.
